| Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.N Engl J Med | PMID 39453837PMC7616743 | 2025-Feb-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39671537无 PMCID | 2025-Feb-20 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;另有 1 张未列出。 | PMID 39700502PMC11867134 | 2025-Feb-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39976417无 PMCID | 2025-Feb-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial.Br J Dermatol | PMID 39437312无 PMCID | 2025-Feb-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Longitudinal validity of the Hyperhidrosis Quality of Life Index (HidroQoL©) in a phase IIIb clinical trial population with hyperhidrosis: responsiveness and meaningful change.Br J Dermatol | PMID 39467334无 PMCID | 2025-Feb-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.Aesthet Surg J | PMID 39475143PMC11834979 | 2025-Feb-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis.Br J Dermatol | PMID 39657020无 PMCID | 2025-Feb-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.Signal Transduct Target Ther | PMID 39956849PMC11830773 | 2025-Feb-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn's Disease Activity Index: psychometric evaluation in adults with Crohn's disease.J Patient Rep Outcomes | PMID 39962027PMC11833035 | 2025-Feb-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome.BMC Cancer | PMID 39962445PMC11831840 | 2025-Feb-17 | 0.85 | The study is a randomized Phase II/III trial of human cancer patients receiving a drug (capecitabine). However, it does not meet the core eligibility criteria: the primary endpoint is not a time-to-event efficacy outcome (it is the incidence of an adverse event), and the intervention under study is a non-drug cream, not a drug. | 待处理 |
| Comparative analysis of intestinal tumor segmentation in PET CT scans using organ based and whole body deep learning.BMC Med Imaging | PMID 39962481PMC11834234 | 2025-Feb-17 | 0.90 | The record describes a phase III randomized trial, but the reported outcomes are technical (Dice scores, precision, recall, F1-score for tumor segmentation) and not clinical efficacy endpoints like survival, progression, or recurrence. | 待处理 |
| Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39913282无 PMCID | 2025-Feb-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis.Med | PMID 39368474PMC12239942 | 2025-Feb-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma.Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39395411无 PMCID | 2025-Feb-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.N Engl J Med | PMID 39282913PMC11821447 | 2025-Feb-13 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 已完成 |
| Routine Spironolactone in Acute Myocardial Infarction.N Engl J Med | PMID 39555814无 PMCID | 2025-Feb-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Colchicine in Acute Myocardial Infarction.N Engl J Med | PMID 39555823无 PMCID | 2025-Feb-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.Antimicrob Agents Chemother | PMID 39699245PMC11823660 | 2025-Feb-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial.Sci Rep | PMID 39948076PMC11825916 | 2025-Feb-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency.Nutrients | PMID 40005002PMC11857939 | 2025-Feb-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer.J Clin Oncol | PMID 39378393无 PMCID | 2025-Feb-10 | 0.80 | The trial is a Phase II randomized trial evaluating radiation fractionation schedules (non-drug intervention) with a primary endpoint of adverse cosmesis, not a time-to-event efficacy endpoint. It does not meet the criteria for drug intervention, Phase III, or time-to-event outcomes. | 待处理 |
| Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39442070无 PMCID | 2025-Feb-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.J Clin Oncol | PMID 39671534PMC11798714 | 2025-Feb-10 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 已完成 |
| Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.Cancer Cell | PMID 39933898无 PMCID | 2025-Feb-10 | 0.80 | While the record describes a human, randomized, phase III oncology trial, the abstract does not report the required survival, progression, recurrence, death, or related efficacy outcomes. It is a biomarker/prognostic analysis, not an efficacy report. | 待处理 |
| Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis.Eur Heart J Cardiovasc Pharmacother | PMID 39380152PMC11805688 | 2025-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease.Inflamm Bowel Dis | PMID 39231444PMC11808569 | 2025-Feb-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.N Engl J Med | PMID 39258838无 PMCID | 2025-Feb-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study.Oncologist | PMID 39265970PMC11883150 | 2025-Feb-06 | 0.95 | Single-arm phase II safety study of a supportive care agent; not a randomized controlled trial and does not report definitive oncology efficacy outcomes such as survival, progression, or recurrence. | 待处理 |
| Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.N Engl J Med | PMID 39453772无 PMCID | 2025-Feb-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Atrasentan in Patients with IgA Nephropathy.N Engl J Med | PMID 39460694无 PMCID | 2025-Feb-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China.Vaccine | PMID 39729925无 PMCID | 2025-Feb-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study.Oncologist | PMID 39912344PMC11799859 | 2025-Feb-06 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.Clin Infect Dis | PMID 38995684PMC11797386 | 2025-Feb-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39798514无 PMCID | 2025-Feb-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine.J Infect Dis | PMID 38970327PMC11793055 | 2025-Feb-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection.J Infect Dis | PMID 39172627PMC11793051 | 2025-Feb-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer.Jpn J Clin Oncol | PMID 39354670无 PMCID | 2025-Feb-04 | 0.45 | The record describes the protocol of a randomized phase III trial with a drug intervention in oncology, but the primary endpoint is stomatitis incidence, not a time-to-event efficacy endpoint (e.g., OS, PFS). Furthermore, the abstract presents aims and design, not formal trial results. | 待处理 |
| Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.J Infect Dis | PMID 39400063PMC11793053 | 2025-Feb-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early Neurologic Deterioration and Efficacy of Dual Antiplatelet in Anterior Versus Posterior Circulation Stroke.J Am Heart Assoc | PMID 39846303PMC12074704 | 2025-Feb-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study.Arthritis Res Ther | PMID 39905436PMC11792409 | 2025-Feb-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab.J Headache Pain | PMID 39901101PMC11792349 | 2025-Feb-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.JAMA Netw Open | PMID 39960672PMC11833520 | 2025-Feb-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis.J Bone Miner Res | PMID 39656908PMC11789382 | 2025-Feb-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared With Esomeprazole in Erosive Esophagitis.Am J Gastroenterol | PMID 38976448无 PMCID | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.Am J Gastroenterol | PMID 39140490PMC11774195 | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 39299550无 PMCID | 2025-Feb-01 | 0.90 | The trial is an oncology Phase III randomized trial with time-to-event endpoints, but the intervention (TACE ± EBRT) is not a drug-containing intervention as defined for this cohort; it is a locoregional/radiation-based therapy. | 待处理 |
| Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01).Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39326505无 PMCID | 2025-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.JAMA Cardiol | PMID 39332395PMC11581494 | 2025-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An Exploratory Analysis of the Conditional Neurocognitive Function Failure Risk in Patients Receiving Whole Brain Radiation Therapy for Brain Metastases on NRG Oncology CC001.Int J Radiat Oncol Biol Phys | PMID 39332644无 PMCID | 2025-Feb-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |